| A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) (NCT06925750) | Merck Sharp & Dohme LLC | 2025-05-12 |
| A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012) (NCT06893081) | Merck Sharp & Dohme LLC | 2025-04-28 |
| A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) (NCT06894771) | Merck Sharp & Dohme LLC | 2025-04-23 |
| Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) (NCT06814145) | Merck Sharp & Dohme LLC | 2025-04-16 |
| A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009) (NCT06580587) | Merck Sharp & Dohme LLC | 2025-04-15 |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (NCT06843447) | Merck Sharp & Dohme LLC | 2025-04-15 |
| A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060) (NCT06891066) | Merck Sharp & Dohme LLC | 2025-04-14 |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) (NCT06890884) | Merck Sharp & Dohme LLC | 2025-04-11 |
| A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (NCT06824467) | Merck Sharp & Dohme LLC | 2025-04-09 |
| A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010) (NCT06814119) | Merck Sharp & Dohme LLC | 2025-04-07 |
| A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010) (NCT06814132) | Merck Sharp & Dohme LLC | 2025-04-07 |
| A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035) (NCT06880874) | Merck Sharp & Dohme LLC | 2025-04-02 |
| A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) (NCT06864169) | Merck Sharp & Dohme LLC | 2025-04-01 |
| A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035) (NCT06903715) | Merck Sharp & Dohme LLC | 2025-03-28 |
| A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) (NCT06829199) | Merck Sharp & Dohme LLC | 2025-03-26 |
| Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) (NCT06788912) | Merck Sharp & Dohme LLC | 2025-03-20 |
| A Study of MK-8527 in Healthy Adult Participants (MK-8527-013) (NCT06826989) | Merck Sharp & Dohme LLC | 2025-03-19 |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (NCT06841354) | Merck Sharp & Dohme LLC | 2025-03-16 |
| A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) (NCT06833073) | Merck Sharp & Dohme LLC | 2025-03-11 |
| A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005) (NCT06818968) | Merck Sharp & Dohme LLC | 2025-02-27 |
| A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) (NCT06780137) | Merck Sharp & Dohme LLC | 2025-02-27 |
| Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) (NCT06686394) | Merck Sharp & Dohme LLC | 2025-02-26 |
| A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants (NCT06816043) | Merck Sharp & Dohme LLC | 2025-02-21 |
| A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) (NCT06797674) | Merck Sharp & Dohme LLC | 2025-02-10 |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (NCT06717347) | Merck Sharp & Dohme LLC | 2025-01-27 |
| A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) (NCT06395090) | Merck Sharp & Dohme LLC | 2025-01-15 |
| A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034) (NCT06719544) | Merck Sharp & Dohme LLC | 2025-01-02 |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) (NCT06637423) | Merck Sharp & Dohme LLC | 2024-12-20 |
| A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012) (NCT06633419) | Merck Sharp & Dohme LLC | 2024-12-18 |
| A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) (NCT06721156) | Merck Sharp & Dohme LLC | 2024-12-16 |
| A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001). (NCT06655324) | Merck Sharp & Dohme LLC | 2024-12-05 |
| A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (NCT06667700) | Merck Sharp & Dohme LLC | 2024-12-02 |
| Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (NCT06428396) | Merck Sharp & Dohme LLC | 2024-11-27 |
| Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) (NCT06651281) | Merck Sharp & Dohme LLC | 2024-11-25 |
| A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032) (NCT06643377) | Merck Sharp & Dohme LLC | 2024-11-22 |
| A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) (NCT06664801) | Merck Sharp & Dohme LLC | 2024-11-14 |
| Safety and Immunogenicity of V540B in Healthy Adults (V540B-002). (NCT06623409) | Merck Sharp & Dohme LLC | 2024-11-12 |
| Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) (NCT06596694) | Merck Sharp & Dohme LLC | 2024-11-03 |
| A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033) (NCT06609512) | Merck Sharp & Dohme LLC | 2024-10-21 |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (NCT06623422) | Merck Sharp & Dohme LLC | 2024-10-21 |
| A Study of MK-2060 in Healthy Participants (MK-2060-016) (NCT06582602) | Merck Sharp & Dohme LLC | 2024-10-15 |
| A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) (NCT06504394) | Merck Sharp & Dohme LLC | 2024-10-14 |
| A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031) (NCT06597760) | Merck Sharp & Dohme LLC | 2024-10-07 |
| A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003) (NCT06586606) | Merck Sharp & Dohme LLC | 2024-10-03 |
| Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020) (NCT06596668) | Merck Sharp & Dohme LLC | 2024-10-02 |
| A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001) (NCT06611033) | Merck Sharp & Dohme LLC | 2024-09-25 |
| Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010) (NCT06575595) | Merck Sharp & Dohme LLC | 2024-09-24 |
| A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030) (NCT06575959) | Merck Sharp & Dohme LLC | 2024-09-20 |
| Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (NCT06469944) | Merck Sharp & Dohme LLC | 2024-09-20 |
| A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) (NCT06566989) | Merck Sharp & Dohme LLC | 2024-09-19 |
| A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006) (NCT06567002) | Merck Sharp & Dohme LLC | 2024-09-09 |
| A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009) (NCT06575933) | Merck Sharp & Dohme LLC | 2024-09-03 |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) (NCT06395103) | Merck Sharp & Dohme LLC | 2024-08-16 |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (NCT06445972) | Merck Sharp & Dohme LLC | 2024-08-07 |
| Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) (NCT06482112) | Merck Sharp & Dohme LLC | 2024-07-29 |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (NCT06459180) | Merck Sharp & Dohme LLC | 2024-07-24 |
| Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) (NCT06456346) | Merck Sharp & Dohme LLC | 2024-07-16 |
| A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044) (NCT06609161) | Merck Sharp & Dohme LLC | 2024-07-16 |
| A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) (NCT06460961) | Merck Sharp & Dohme LLC | 2024-07-14 |
| A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) (NCT06465186) | Merck Sharp & Dohme LLC | 2024-07-12 |
| A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011) (NCT06554639) | Merck Sharp & Dohme LLC | 2024-07-11 |
| A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) (NCT06450366) | Merck Sharp & Dohme LLC | 2024-07-08 |
| A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028) (NCT06625814) | Merck Sharp & Dohme LLC | 2024-07-08 |
| MSD Belzutifan PAS (NCT06554730) | Merck Sharp & Dohme LLC | 2024-06-30 |
| A Study of Calderasib (MK-1084) Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006) (NCT06687759) | Merck Sharp & Dohme LLC | 2024-06-26 |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) (NCT06393374) | Merck Sharp & Dohme LLC | 2024-06-24 |
| A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008) (NCT06295796) | Merck Sharp & Dohme LLC | 2024-06-20 |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) (NCT06428409) | Merck Sharp & Dohme LLC | 2024-06-20 |
| A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015) (NCT06701305) | Merck Sharp & Dohme LLC | 2024-06-13 |
| Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002) (NCT06829225) | Merck Sharp & Dohme LLC | 2024-06-13 |
| A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007) (NCT06662396) | Merck Sharp & Dohme LLC | 2024-06-13 |
| Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (NCT06305754) | Merck Sharp & Dohme LLC | 2024-06-11 |
| Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (NCT06422143) | Merck Sharp & Dohme LLC | 2024-06-10 |
| A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) (NCT06430801) | Merck Sharp & Dohme LLC | 2024-06-05 |
| A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) (NCT06345729) | Merck Sharp & Dohme LLC | 2024-05-24 |
| A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) (NCT06351631) | Merck Sharp & Dohme LLC | 2024-05-23 |
| A Study of the Effect of Itraconazole and Phenytoin on Calderasib (MK-1084) in Healthy Adults (MK-1084-008) (NCT06719557) | Merck Sharp & Dohme LLC | 2024-05-20 |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (NCT06353386) | Merck Sharp & Dohme LLC | 2024-05-20 |
| A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (NCT06356311) | Merck Sharp & Dohme LLC | 2024-05-03 |
| A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014) (NCT06821334) | Merck Sharp & Dohme LLC | 2024-04-23 |
| A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027) (NCT06772792) | Merck Sharp & Dohme LLC | 2024-04-23 |
| A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) (NCT06294912) | Merck Sharp & Dohme LLC | 2024-04-18 |
| A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (NCT06295809) | Merck Sharp & Dohme LLC | 2024-04-18 |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (NCT06312176) | Merck Sharp & Dohme LLC | 2024-04-14 |
| A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). (NCT06307431) | Merck Sharp & Dohme LLC | 2024-04-10 |
| A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020) (NCT06273774) | Merck Sharp & Dohme LLC | 2024-04-08 |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (NCT06312137) | Merck Sharp & Dohme LLC | 2024-04-03 |
| A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026) (NCT06772779) | Merck Sharp & Dohme LLC | 2024-04-01 |
| Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (NCT06285240) | Merck Sharp & Dohme LLC | 2024-03-28 |
| A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) (NCT06305767) | Merck Sharp & Dohme LLC | 2024-03-28 |
| A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003) (NCT06619665) | Merck Sharp & Dohme LLC | 2024-03-19 |
| A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025) (NCT06691906) | Merck Sharp & Dohme LLC | 2024-03-18 |
| Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) (NCT06242691) | Merck Sharp & Dohme LLC | 2024-02-28 |
| A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003) (NCT06692647) | Merck Sharp & Dohme LLC | 2024-02-09 |
| A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058) (NCT06811246) | Merck Sharp & Dohme LLC | 2024-02-07 |
| Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004) (NCT06179407) | Merck Sharp & Dohme LLC | 2024-01-24 |
| A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055) (NCT06719570) | Merck Sharp & Dohme LLC | 2024-01-23 |
| A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023) (NCT06699329) | Merck Sharp & Dohme LLC | 2024-01-22 |
| A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (NCT06177912) | Merck Sharp & Dohme LLC | 2024-01-18 |
| Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043) (NCT05115838) | Merck Sharp & Dohme LLC | 2024-01-04 |